Creutzfeldt-Jakob Disease Devastates Israeli Families with No Known Cure

Creutzfeldt-Jakob disease (CJD), a rare and fatal neurodegenerative disorder, affects about 30 Israelis annually, with a notably high hereditary incidence among Libyan and Tunisian Jewish communities. The disease, often confused with "mad cow disease" due to a shared prion protein mechanism, causes rapid neurological decline including memory loss, vision problems, and impaired movement, typically leading to death within a year of symptom onset.

Families living under the shadow of CJD recount the swift deterioration and emotional toll. For example, Maya Yeshayahu from Tzur Yitzhak died at 42 after months of misdiagnoses ranging from stroke to psychiatric disorders. Her sister, Racheli, emphasized the need for doctors to consider family history in neurological cases, especially among Libyan descent, to avoid delayed diagnosis. Another case involves Daniel, a man in his 50s from southern Israel, who was diagnosed early enough to join a clinical trial for an experimental drug in the US, offering some hope amid the otherwise grim prognosis.

The hereditary form of CJD is linked to a genetic mutation prevalent in certain Israeli communities, disproving earlier theories that dietary habits caused the disease. Dr. Nurit Omer of Ichilov Medical Center, a leading expert on CJD in Israel, explains that while two-thirds of cases are genetic, one-third are sporadic with no known cause. She highlights the psychological burden on families, many of whom avoid genetic testing due to the absence of effective treatments.

Despite the lack of a cure, Israeli researchers are advancing studies to identify early biological markers and are participating in international trials of gene-silencing therapies aimed at slowing disease progression. Preventive measures such as in vitro fertilization with embryo selection are available and fully funded in Israel for at-risk families. Advocacy groups like the Creutzfeldt-Jakob Israel Foundation, founded by affected families, support research and patient care.

Dr. Omer stresses the urgency of early detection and hopes future treatments will enable intervention before symptoms appear, potentially preventing or delaying disease onset. Until then, families continue to cope with the devastating impact of a disease that, to date, has no survivors.